fig1

Figure 1. KIR-targeting strategies to improve NK therapy. (A) CAR target tumour antigens can be transferred to CAR-NK cells by trogocytosis^[11]. Co-expression of a tumour targeting CAR (aCAR) with an inhibitory KIR-based CAR (iCAR) construct recognizing an antigen expressed on NK cells reduces fratricide of CAR-NK cells that are positive for the target tumour antigen due to trogocytosis. (B) Summary of current approaches under investigation targeting the KIR in NK cell therapeutics. Parts of this figure were generated using Servier Medical Art images licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/).